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Abstract
 
CC chemokine receptor (CCR)4, a high affinity receptor for the CC chemokines thymus and
activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC), is ex-
pressed in the thymus and spleen, and also by peripheral blood T cells, macrophages, platelets,
and basophils. Recent studies have shown that CCR4 is the major chemokine receptor ex-
pressed by T helper type 2 (Th2) polarized cells. To study the in vivo role of CCR4,
 
 
 
we have
generated CCR4-deficient (CCR4
 
2
 
/
 
2
 
) mice by gene targeting. CCR4
 
2
 
/
 
2
 
 mice developed
normally. Splenocytes and thymocytes isolated from the CCR4
 
2
 
/
 
2
 
 mice failed to respond to
the CCR4 ligands TARC and MDC, as expected, but also surprisingly did not undergo
chemotaxis in vitro in response to macrophage inflammatory protein (MIP)-1
 
a
 
. The CCR4
deletion had no effect on Th2 differentiation in vitro or in a Th2-dependent model of allergic
airway inflammation. However, CCR4
 
2
 
/
 
2
 
 mice exhibited significantly decreased mortality on
administration of high or low dose bacterial lipopolysaccharide (LPS) compared with CCR4
 
1
 
/
 
1
 
mice. After high dose LPS treatment, serum levels of tumor necrosis factor 
 
a
 
, interleukin 1
 
b
 
,
and MIP-1
 
a
 
 were reduced in CCR4
 
2
 
/
 
2
 
 mice, and decreased expression of MDC and MIP-2
mRNA was detected in peritoneal exudate cells. Analysis of peritoneal lavage cells from
CCR4
 
2
 
/
 
2
 
 mice by flow cytometry also revealed a significant decrease in the F4/80
 
1
 
 cell popu-
lation. This may reflect a defect in the ability of the CCR4
 
2
 
/
 
2
 
 macrophages to be retained in
the peritoneal cavity. Taken together, our data reveal an unexpected role for CCR4 in the in-
flammatory response leading to LPS-induced lethality.
Key words: CC chemokine receptor 4 • lipopolysaccharide • endotoxic shock • F4/80 
antigen • T helper type 2 cells
 
Introduction
 
Chemokines are a superfamily of small proteins involved
both in routine leukocyte trafficking and in the activation
and recruitment of specific cell populations to sites of
inflammation and infection. There are four classes of
chemokines, named according to the spacing of the first
two of a conserved four-cysteine motif: CC, CXC, C, and
CX
 
3
 
C. The majority of chemokines belong to the CC and
CXC subfamilies. For the C and CX
 
3
 
C subfamilies, only
one member has been identified to date, lymphotactin and
fractalkine (or neurotactin), respectively (1, 2). The biolog-
ical activity of chemokines is mediated by their interaction
with a family of seven-transmembrane G protein–coupled
receptors. To date, there are published reports for five
CXC chemokine–specific receptors, nine CC, a CX
 
3
 
C,
and a C chemokine receptor as well as the Duffy antigen
and several virally encoded chemokine receptors (3, 4). In
vitro studies have shown that most chemokines are able to
bind and activate more than one chemokine receptor, and
the majority of chemokine receptors bind multiple ligands
although there are exceptions. Yet in spite of this apparent
redundancy, there are now increasing numbers of reports
in the literature associating specific chemokine receptor–
ligand pairs with particular disease states or tissue-specific
lymphocyte homing. Much of this information has been
obtained from studies of chemokine or chemokine recep-
tor knockout mice.
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CCR4 Knockout Mice Are Resistant to Endotoxic Shock
 
We have previously reported the molecular cloning of
both human and murine CC chemokine receptor (CCR)
 
1
 
4 (5, 6). Although originally identified as a receptor for
macrophage inflammatory protein (MIP)-1
 
a
 
 and regulated
upon activation, normal T cell expressed and secreted
chemokine (RANTES), CCR4 is in fact a high affinity re-
ceptor for two recently described CC chemokines, thymus
and activation-regulated chemokine (TARC) (7) and mac-
rophage-derived chemokine (MDC) (8). CCR4 mRNA is
expressed predominantly in the thymus, spleen, and in pe-
ripheral blood leukocytes, including T cells, basophils,
monocytes (5), macrophages, and platelets (9). In addition,
several reports have shown that CCR4 is highly expressed
by human T cells polarized towards the Th2 phenotype
(10–12). These Th2 cells are also responsive to the CCR4
ligands TARC and MDC, leading investigators to suggest a
role for CCR4 in the development of Th2 responses. Fi-
nally, a recent report has shown that CCR4 is also ex-
pressed on all skin homing T cells expressing cutaneous
lymphocyte antigen (CLA) (13).
To study the role of CCR4 in vivo, we have generated
CCR4-deficient mice by gene targeting. Here, we show
that in spite of the reported high level expression of CCR4
on human Th2-polarized cells, CCR4 deletion had no ef-
fect on the development of the response in a classical Th2-
dependent murine model of airway inflammation. How-
ever, CCR4
 
2
 
/
 
2
 
 mice showed an unexpected resistance to
the lethal effects of LPS in two models of LPS-induced en-
dotoxic shock.
 
Materials and Methods
 
Generation of CCR4-deficient Mice.
 
The murine (m)CCR4
gene was isolated from an HM-1 embryonic stem (ES) cell library
in 
 
l
 
FIXII vector (Stratagene) by plaque hybridization using mu-
rine CCR4 cDNA as a probe (6). Two unique clones of 12.18
and 13.08 kb were shown to contain the mCCR4 coding se-
quence by PCR, using specific primers (6). An 8.5-kb fragment
of genomic DNA confirmed to contain the CCR4 coding se-
quence by Southern blotting was subcloned into pBluescript II
SK
 
2
 
 to generate pCCR4. The entire CCR4 coding sequence
was then removed as an NheI-HpaI fragment and replaced with a
neo cassette (derived from pMC1neoPolyA; CLONTECH
Laboratories, Inc.). The resulting construct was digested with
EcoRV and Eco47-3, and religated to generate a plasmid con-
taining a long arm of homology of 4,904 bp and a short arm of
homology of 1,318 bp. Finally, a thymidine kinase (tk) cassette
was inserted into the HindIII-XhoI site of the plasmid to produce
the targeting vector. The targeting vector was linearized with
NotI and electroporated into HM-1 ES cells as described previ-
ously (14). Gancyclovir and G418-resistant clones were selected.
DNA was isolated from resistant clones using DNAzol (GIBCO
BRL), and the presence of the transgene was detected by PCR
and verified by Southern hybridization on PstI-digested genomic
DNA, using a 466-bp probe derived by AvrII-NsiI digestion of
pCCR4. Seven independent transgene-containing ES cell clones
were used to produce chimeric mice by blastocyst injection ac-
cording to standard procedures (15). Two 100% chimeric males
derived from two independent ES clones were mated with a
100% chimeric female to generate heterozygous CCR4
 
1
 
/
 
2
 
 mice,
and littermates from the matings of CCR4
 
1
 
/
 
2
 
 mice were ana-
lyzed for the presence of homozygous CCR4
 
2
 
/
 
2
 
 mice by South-
ern blot analysis or by PCR on tail DNA. The sequences of the
PCR primers used are: (primer 1, neomycin gene) 5
 
9
 
-CGCT-
TCCTCGTGCTTTACGGTAT; (primer 2, CCR4 3
 
9
 
 un-
translated region) 5
 
9
 
-ATAGCCTTGGCTGGTCTGGAACTA;
(primer 3, mCCR4 coding region sense primer) 5
 
9
 
-CCAAA-
GATGAATGCCACAGAGGTCACAG; (primer 4, mCCR4
coding region antisense primer) 5
 
9
 
-TTACAAAGCGTCACG-
GAAGTCATG.
 
Reverse Transcriptase PCR.
 
Total RNA was isolated from
thymocytes, splenocytes, or peritoneal lavage cells using Trizol™
(GIBCO BRL). 1 
 
m
 
g of total RNA from thymocytes and spleno-
cytes or total RNA from 10
 
6
 
 peritoneal exudate cells was reverse
transcribed using Superscript™ (GIBCO BRL) and oligo dT
 
12–18
 
primer according to the manufacturer’s instructions. One twenti-
eth of the cDNA synthesis reaction was then subjected to 25 cy-
cles of PCR using AmpliTaq™ (PerkinElmer) and PCR primers
based on the EMBL/GenBank/DDBJ database entries for MIP-2
(X53798), mMDC (AF052505), and mCCR4 (X90862). PCR
products were analyzed on 1% agarose gels stained with ethidium
bromide, and bands migrating at the correct molecular weight
were verified by direct sequencing. For semiquantitative reverse
transcriptase (RT)-PCR, bands were quantitated using Kodak
Digital Science v1.0 software and results are expressed as arbitrary
units of mRNA.
 
In Vitro Differentiation of Th1 and Th2 Cells.
 
CD8
 
1
 
 and Ig
 
1
 
depleted cells from lymph nodes and spleens of naive CCR4
 
1
 
/
 
1
 
and CCR4
 
2
 
/
 
2
 
 mice were cultured for 4 d on plates coated with
an anti-CD3 antibody (145-2C11; BD PharMingen) as described
previously (16) in the presence of either murine IL-12 (500 pg/
ml; R&D Systems) plus anti–IL-4 mAb (10 
 
m
 
g/ml) or murine
IL-4 (500 U/ml; ImmunoKontact) plus anti–IFN-
 
g
 
 mAb (10
 
m
 
g/ml; BD PharMingen). After a 5-d culture period, cells were
washed and restimulated for 24 h at a density of 2 
 
3
 
 10
 
5
 
 cells per
well on an anti-CD3–coated 96-well plate (Costar) in the pres-
ence of murine IL-2 (50 U/ml; R&D Systems).
 
Animals and Treatments.
 
Homozygous CCR4
 
2
 
/
 
2
 
 mice were
backcrossed with C57BL/6 mice (Centre d’Elevage Janvier) for
four generations. Age- and weight-matched CCR4
 
2
 
/
 
2
 
 and
CCR4
 
1
 
/
 
1
 
 littermates from heterozygote (CCR4
 
1
 
/
 
2
 
) matings
from the fourth backcross were used in this study to control for
strain background. Mice (20–25 g) of either sex were immunized
intraperitoneally with 10 
 
m
 
g of OVA (A-5503; Sigma-Aldrich) in
0.2 ml of alum (Serva). Control mice received an injection of sa-
line (0.9% wt/vol NaCl) alone. 14 d later, mice were anesthe-
tized by inhaled 2% FORENE™ (Abbott) and 50 
 
m
 
g of OVA
was administered to the lungs (in 50 
 
m
 
l of saline) intranasally as
described previously (17). Control mice received 50 
 
m
 
l saline
only. This procedure was repeated daily for 5 d. Animals were fi-
nally killed by lethal injection of 60 mg/kg pentobarbital. Stu-
dent’s 
 
t
 
 test was used for statistical analysis, except that for the
analysis of the survival curves, we performed the log rank test
(two-tailed).
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; BALF, BAL
fluid; BHR, bronchial hyperreactivity; CCR, CC chemokine receptor;
D-gal, 
 
d
 
-galactosamine; ES, embryonic stem; MCh, methacholine;
MDC, macrophage-derived chemokine; MIP, macrophage inflammatory
protein; Penh, enhanced pause; RANTES, regulated upon activation,
normal T cell expressed and secreted chemokine; RT, reverse tran-
scriptase; TARC, thymus and activation-regulated chemokine; Tlr4,
Toll-like receptor 4. 
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Phenol-extracted bacterial LPS from 
 
Escherichia coli
 
 055:B5
(List Biological Laboratories) was administered at 60, 90, and 120
mg/kg intraperitoneally for the high dose LPS shock model. For
the low dose LPS shock model, mice received 1, 2, and 4 
 
m
 
g of
LPS with 8 mg 
 
d
 
-galactosamine (D-gal; Fluka) in 0.5 ml saline.
Animals were killed by CO
 
2
 
 asphyxiation at the time points indi-
cated in the figures.
 
Evaluation of Bronchial Hyperresponsiveness.
 
Bronchial hyperre-
activity (BHR) was measured by recording respiratory pressure
curves by whole body plethysmography (18) in response to in-
haled methacholine (MCh; Sigma-Aldrich) using a Buxco
 
®
 
 appa-
ratus (EMKA Technologies). The airway reactivity was expressed
in enhanced pause (Penh) as described previously (19).
 
Analysis of Blood and Lavage Fluids.
 
Blood (20 
 
m
 
l) was col-
lected from the retroorbital plexus of mice into a heparinized mi-
cropipette, then transferred to a Unopette microcollection system
for platelet determination (Becton Dickinson). Three indepen-
dent samples of platelets were counted in a hemocytometer. A
minimum of 100 cells were counted, and the arithmetic mean of
the three counts was calculated (20).
OVA-specific IgM, IgG1, IgG2a, and IgE titers were measured
in serum samples obtained 3 d after the final intranasal treatment
with OVA using a standard ELISA protocol (19). Quantification
of murine TNF-
 
a
 
 in serum and in culture supernatant and IL-1
 
b
 
,
IL-6, and MIP-1
 
a
 
 in serum was determined using cytokine-spe-
cific ELISAs as per the manufacturer’s protocol (R&D Systems).
Bronchoalveolar lavage (BAL) and peritoneal lavage cells were
harvested and differential cell counts were performed on cytospin
preparations stained with Diff-Quik™ (Baxter Diagnostics). A
minimum of 200 cells were counted per field, with 3 fields per
sample for BAL, and 5 fields per sample for peritoneal lavage.
For phenotypic analysis of peritoneal cells by flow cytometry, la-
vaged cells were resuspended at 10
 
6
 
 cells/ml in PBS containing 1%
BSA and 0.01% azide (FACS buffer). Cells were incubated with Fc
block (BD PharMingen) for 10 min at 4
 
8
 
C, washed twice with
FACS buffer, then incubated for 20 min with FITC-labeled rat
anti–mouse F4/80 antibody (Serotec). Cells were washed twice,
resuspended in 200 
 
m
 
l FACS buffer, and analyzed on a Becton
Dickinson FACScan™ flow cytometer with CELLQuest™
software.
 
Chemotaxis Assays.
 
Spleens from CCR4
 
1
 
/
 
1
 
 and CCR4
 
2
 
/
 
2
 
mice were dispersed through a 70-
 
m
 
m nylon cell strainer (Becton
Dickinson). Erythrocytes were removed by hypotonic lysis. Cells
were harvested by centrifugation and resuspended in RPMI me-
dium containing 5% FCS and 2 mM glutamine. Chemotaxis as-
says were performed using the micro-Boyden chamber method
with 5-
 
m
 
m filters (21). Recombinant human and mouse chemo-
kines were purchased from R&D Systems or made in house.
 
Results and Discussion
 
The murine CCR4 gene was deleted through homolo-
gous recombination using the targeting vector shown in
Fig. 1 a. Targeted ES cells were used to generate chimeric
mice, which transmitted the transgene through the germ-
line. Southern blot analysis confirmed that the CCR4 gene
had been deleted using a DNA probe located in the 5
 
9
 
noncoding region of the gene (Fig. 1 b). PCR was also
used to confirm that the CCR4 coding sequence had in-
deed been deleted while confirming the presence of the
neomycin transgene and 3
 
9 
 
untranslated sequence of
CCR4. The CCR4 knockout mice were viable, appeared
 
to develop normally, and showed no overt morphological
or behavioral defects in the unstressed state. RT-PCR was
used to demonstrate that the mRNA for CCR4 was not
present in the thymus, spleen (Fig. 1 c), or peritoneal cells
(Fig. 1 d) of targeted animals.
The ability of splenocytes and thymocytes, isolated from
the targeted and wild-type mice, to migrate in response to
the proposed CCR4 ligands was then assessed. Splenocytes
(Fig. 1 e) and thymocytes (data not shown) from CCR4
 
2
 
/
 
2
 
mice had no chemotactic response to TARC or MDC,
whereas splenocytes from CCR4
 
1
 
/
 
1
 
 mice responded with
the characteristic dose–response curves, confirming that
the gene deleted in this study is an endogenous TARC
and MDC receptor. Surprisingly, splenocytes isolated from
the CCR4
 
2
 
/
 
2
 
 mice did not respond to human MIP-1
 
a
 
(Fig. 1 e) or to murine MIP-1
 
a
 
 (data not shown) in at least
four independent experiments. However, the response to
human RANTES was similar in both groups of mice (Fig.
1 e). Murine RANTES receptors described to date (CCR1,
CCR5, and CCR3) have also been shown to bind and
signal in response to MIP-1
 
a
 
 in vitro. Yet RT-PCR anal-
ysis of the cells used in the study confirmed that deletion
of the CCR4 gene did not interfere with expression of
these other receptors (data not shown). This result sug-
gested that in these cell types, CCR4 is a physiological re-
ceptor for MIP-1
 
a
 
. At present, we are unable to explain
this astonishing result. However, most of the data on
chemokine receptor ligand specificity has been obtained
from in vitro studies. As such it is possible that in vivo,
other factors affect chemokine receptor selectivity. Alter-
natively, our observations could reflect the need for coop-
erativity between distinct chemokine receptors to generate
ligand specificity.
The role of CCR4 in the in vitro differentiation of T
cells was addressed next. Naive CD4
 
1
 
 T cells were cul-
tured for 4 d on plates coated with an anti-CD3 antibody
either in the presence of IL-12 plus anti–IL-4 antibody,
which induces Th1 cell differentiation, or in the presence
of IL-4 plus anti–IFN-
 
g
 
 antibody, which induces Th2 cell
differentiation. Cells were then restimulated with the anti-
CD3 antibody for 24 h. CD4
 
1
 
 T cells initially cultured in
the presence of IL-4 showed no significant difference in the
production of IL-4 (CCR4
 
1
 
/
 
1
 
 T cells, 105 
 
6
 
 15 pg/ml;
CCR4
 
2
 
/
 
2
 
 T cells, 190 
 
6
 
 10 pg/ml) after restimulation.
Likewise, T cells cultured with IL-12 produced comparable
levels of IFN-
 
g
 
 (CCR4
 
1
 
/
 
1
 
, 76 
 
6
 
 19 ng/ml; CCR4
 
2
 
/
 
2
 
,
49 
 
6 8 ng/ml). These results indicate that in vitro, Th2 and
Th1 cell differentiation was not impaired in the CCR42/2
mice. As in vitro–derived Th2 T cells have previously been
shown to express CCR4, we tested whether the cells used
in this study could respond to CCR4 ligands in chemotaxis
assays. Cells derived from the CCR42/2 mice failed to mi-
grate in response to MDC, whereas cells derived from the
CCR41/1 mice had a robust chemotactic response to
MDC (Fig. 2 a). A similar result was obtained using TARC
(data not shown). In addition, in vitro–derived Th2 T cells
from both wild-type and CCR42/2 mice responded to
RANTES (Fig. 2 a).1758 CCR4 Knockout Mice Are Resistant to Endotoxic Shock
The effect of the CCR4 deletion in vivo was studied us-
ing an OVA-induced murine model of airway inflamma-
tion, a predominantly Th2-associated response (22). Re-
peated intranasal OVA challenges of immunized CCR41/1
and CCR42/2 littermates resulted in a significant increase
in BHR in response to inhaled MCh (3 3 1022 M) com-
pared with saline-challenged mice (Fig. 2 a). Penh values
were 0.8 6 0.1 in saline compared with 1.77 6 0.2 in
OVA-challenged CCR41/1 mice, and 0.64 6 0.11 in saline
compared with 1.88 6 0.33 in OVA-challenged CCR42/2
mice. Comparable OVA-induced eosinophilia was ob-
served both in BALF (Fig. 2 b) and in lung tissue (data not
shown) of CCR41/1 and CCR42/2 littermates, a finding
consistent with the induction of a Th2 response in the air-
ways. In addition, no significant differences were observed
in the BAL fluid (BALF) in either the total cell count or in-
dividual leukocyte populations (eosinophils, macrophages,
lymphocytes, and neutrophils) between OVA-challenged
CCR41/1 and CCR42/2 littermates (Fig. 2 b). To con-
firm that efficient antigen priming had occurred in the pe-
riphery, serum titers of OVA-specific IgM, IgG1, IgG2a,
and IgE were measured. Again, all OVA-specific Ig titers
were comparable in CCR41/1 and CCR42/2 littermates
after OVA sensitization and challenge (Fig. 2 c). Taken to-
gether, our results suggest that deletion of the CCR4 gene
does not impair the development of a Th2 response in vivo
in this model. This is in contrast to the data recently re-
ported by Gonzalo et al. (23), in which the administration
of polyclonal antibodies against MDC, one of the ligands
for CCR4, protected against eosinophilia and BHR. How-
ever, there are several explanations for the differences be-
tween the results. First, there may be an alternative recep-
tor for MDC on activated cells. Second, the genetic
background of mice used in each study may differentially
influence susceptibility. Third, the polyclonal antibodies
used may have depleted MDC binding cells. These hy-
potheses will be tested when specific mAbs against murine
MDC become available.
Figure 1. Targeted disruption of the CCR4 gene. (a) Targeting
strategy. Wild-type CCR4 locus with partial restriction map (top),
targeting vector (middle), and predicted structure of the targeted al-
lele after homologous recombination (bottom). The coding region of
the gene is shown as a black box. The neomycin resistance gene is
light gray and thymidine kinase gene is dark gray. The arrows denote
the position of the PCR primers used to identify ES cell clones ex-
pressing the transgene. The probe used for screening genomic DNA
is shown by the thick black bar (probe). Restriction sites are as fol-
lows: P, PstI; N, NheI; Ns, NsiI; A, AvrI; X, XhoI; E5, EcoRV; Ec,
Eco47-3; H, HpaI; and H3, HindIII. (b) Representative Southern
blot analysis of PstI-digested tail DNA from wild-type (CCR41/1),
heterozygous (CCR41/2), and homozygous knockout mice
(CCR42/2). The expected band sizes of the wild-type allele (4.5 kb)
and the targeted allele (3.4 kb) are indicated by arrows. (c) RT-PCR
analysis of CCR4 mRNA. Spleen (lanes 1–4) and thymus (lanes 5–8)
of CCR41/1 (lanes 1, 2, 5, and 6) and CCR42/2 mice (lanes 3, 4, 7, and 8). (d) RT-PCR analysis of CCR4 mRNA in peritoneal macrophages iso-
lated from CCR41/1 (lanes 1–3) and CCR42/2 mice (lanes 4–6). The predicted band size of CCR4 PCR product indicated by the arrow is 1.1 kb.
(e) Chemotaxis of splenocytes in response to CCR4 ligands. CCR41/1 (open circles) and CCR42/2 mice (filled circles). Results shown are the means
of triplicate determinations for each concentration of chemokine, and are representative of at least four experiments.1759 Chvatchko et al.
CCR4 is also expressed on other cell types, such as
platelets (9), monocytes (5, 24), and macrophages (Parums,
D., and Power, C.A., unpublished data; see also Fig. 1 d).
Therefore, we assessed the effect of the CCR4 deletion
during LPS-induced endotoxic shock, an inflammatory
model in which these cells types have been implicated (25,
26). LPS (60–120 mg/kg) was injected intraperitoneally
into CCR41/1 and CCR42/2 littermates and survival was
assessed daily for 6 d (Fig. 3 a). All CCR41/1 mice died
between 2 and 4 d after LPS injection. In contrast, 14 out
of 15 CCR42/2 mice were alive on day 6, demonstrating
significant resistance to 60 mg/kg LPS (P , 0.001). In-
deed, the CCR42/2 mice were also strikingly resistant to
LPS doses of up to 120 mg/kg. Control mice (saline-
injected CCR42/2 mice, n 5 4, and CCR41/1 mice, n 5
4) remained alive and healthy throughout the 6-d study
(data not shown). Interestingly, during the first few hours
after LPS administration, CCR42/2 mice still showed
signs of endotoxemia such as shivering and lethargy. How-
ever, these effects were visually milder than in the
CCR41/1 mice.
Intraperitoneal injection of a high dose of LPS is fol-
lowed by a marked thrombocytopenia and accumulation of
platelets in the liver and spleen (27). Blood samples from
CCR42/2 and CCR41/1 mice contained similar numbers
of platelets. Furthermore, in an independent experiment, a
superimposable decrease in blood platelet count occurred
in both CCR41/1 (n 5 3) and CCR42/2 mice (n 5 3) in
the first 20 h after injection of high dose LPS (Fig. 3 b), in-
dicating that there was no obvious difference in platelet
mobilization between the two groups. However the plate-
let count returned to normal in the CCR42/2 mice by 5 d
after treatment.
As a comparison, the effect of the CCR4 deletion in a
low dose LPS endotoxic shock model was studied. In this
model, the susceptibility of mice to a low doses of LPS (1,
2, and 4 mg) is enhanced by coinjection of 8 mg of D-gal
(28). Within 24 h of intraperitoneal injection of the LPS
Figure 2. Effect of CCR4 deletion on Th2 responses in vitro and in vivo. (a) Chemotactic response of in vitro–derived Th2 T cells to MDC (top) and
RANTES (bottom). CCR41/1 (open symbols) and CCR42/2 (filled symbols). CCR4-deficient mice develop allergic airway inflammation. (b) Airway
reactivity in response to MCh in CCR41/1 (open symbols) and CCR42/2 (filled symbols) mice after OVA priming followed by intranasal challenge with
saline (circles, n 5 10) or OVA (squares, n 5 13). (c) Total cell count and individual leukocyte populations in BALF. CCR41/1 (white bars, n 5 13) and
CCR42/2 (black bars, n 5 13). (d) OVA-specific Ig serum titers of OVA-primed and challenged mice were measured by ELISA. Data are shown for one
experiment representative of three different experiments, for each parameter measured.1760 CCR4 Knockout Mice Are Resistant to Endotoxic Shock
and D-gal combination, only 1 in 12 of the CCR41/1
mice survived, whereas 9 out of 12 of the CCR42/2 litter-
mates survived when treated with 1 mg of LPS plus D-gal
(P , 0.02; Fig. 3 c), also demonstrating increased resistance
to low dose LPS. However, when administered at 4 mg of
LPS with D-gal, all CCR42/2 mice tested died but with a
6-h delay compared with the wild-type mice.
LPS is known to stimulate the release of proinflamma-
Figure 3. Absence of CCR4 protects against LPS-induced death. (a) Survival
curves of CCR41/1 (open symbols) and CCR42/2 (filled symbols) mice injected in-
traperitoneally with 60 mg/kg (squares, n 5 15), 90 mg/kg (circles, n 5 4), and 120
mg/kg (triangles, n 5 4) of LPS. (b) LPS-induced thrombocytopenia after injection
of LPS (60 mg/kg). CCR41/1 (open squares, n 5 3) and CCR42/2 (filled squares,
n 5 3). (c) Survival curves of CCR41/1 (open symbols) and CCR42/2 (filled symbols)
mice injected intraperitoneally with 1 mg (squares, n 5 12), 2 mg (circles, n 5 4), and
4 mg (triangles, n 5 4) of LPS plus D-gal (8 mg). The data shown are from three dif-
ferent experiments.
Figure 4. Time course of LPS-induced cytokines. Serum levels of TNF-a (a), IL-1b (c), and MIP-1a (d) after 60 mg/kg LPS treatment; and in vitro
production of TNF-a by peritoneal lavage cells stimulated with 1 mg/ml LPS (b). CCR41/1 mice (white bars, n 5 3) and CCR42/2 mice (black bars,
n 5 3). Results shown are representative of at least two different experiments.1761 Chvatchko et al.
tory cytokines such as TNF-a and IL-1b from monocytes,
macrophages, and neutrophils (29). Therefore, the effect of
the high dose LPS response was studied in more detail. A
sharp increase in serum TNF-a levels was observed in
CCR41/1 mice 1.5 h after LPS injection, which returned
to baseline by 4 h after treatment. Interestingly, CCR42/2
mice failed to induce significant levels of serum TNF-a af-
ter LPS injection (P , 0.002 at 1.5 h; Fig. 4 a). Cells iso-
lated by peritoneal lavage from naive CCR42/2 mice pro-
duced significantly lower levels of TNF-a when cultured
for 18 h in the presence of LPS, compared with cells iso-
lated from naive CCR41/1 mice (107 6 11 compared with
201 6 18 pg/ml, P , 0.0079; Fig. 4 b). In addition, a six-
fold decrease in serum IL-1b in CCR42/2 mice was ob-
served 3 h after LPS injection (P , 0.002) compared with
CCR41/1 mice (Fig. 4 c). This suggests that the observed
resistance to LPS may in part be due to decreased TNF-a
and IL-1b production, implying that CCR4 is indirectly
involved in the production of these cytokines. In contrast,
IL-6 production was unaltered (data not shown), suggest-
ing that in CCR42/2 mice the regulation of IL-6 can be
independent from that of TNF-a and IL-1b. Further anal-
ysis of the CCR42/2 samples also revealed a parallel de-
crease in serum MIP-1a levels (P , 0.0249 at 1.5 h; Fig. 4
d), pointing to a possible macrophage defect.
The cellular composition of the peritoneal lavage was
therefore assessed at various times after injection of high
dose LPS. No significant differences were seen in the total
number of cells at early time points. At 24 h after high dose
LPS treatment, the number of neutrophils detected in the
lavage of both groups of mice was comparable (Fig. 5 a).
This is as expected, since to date there is no evidence for
the expression of CCR4 on neutrophils. Furthermore, we
have shown that neutrophils isolated from the peritoneal
cavity of wild-type mice after thioglycollate treatment do
not respond to CCR4 ligands in chemotaxis assays. In ad-
dition, thioglycollate-elicited neutrophils from CCR42/2
mice respond normally to MIP-1a and MIP-2 (our unpub-
Figure 5. Analysis of peritoneal lavage
cells after high dose LPS treatment. Quanti-
tation of (a) neutrophils and (b) macro-
phages on cytospin slides prepared from the
peritoneal lavage at times indicated. Effect
of LPS treatment on macrophage chemo-
kine expression by peritoneal cells as mea-
sured by semiquantitative RT-PCR: (c)
MIP-2 and (d) MDC. CCR41/1 mice
(white bars, n 5 3) and CCR42/2 mice
(black bars, n 5 3). Analysis of F4/80 ex-
pression by peritoneal cells using flow cy-
tometry (e) before LPS treatment, and (f)
24 h after LPS treatment. CCR41/1 (thick
black line) and CCR42/2 (thin black line).
The results shown represent the results of
one out of two independent experiments.1762 CCR4 Knockout Mice Are Resistant to Endotoxic Shock
lished data). However, CCR42/2 mice had significantly
fewer macrophages than CCR41/1 mice (P , 0.0099; Fig.
5 b). These findings were consistent with the observed de-
crease in the mRNA expression of the macrophage-associ-
ated chemokines MIP-2 (30) and MDC (31) (Fig. 5, c and
d). We confirmed the apparent differences in macrophage
numbers seen on the cytospins by FACS® analysis for mac-
rophage markers. We found decreased numbers of CD11b1
and CD141 cells (data not shown) and an absence or se-
verely reduced number of F4/80-expressing cells in the
CCR42/2 mice compared with the CCR41/1 mice 24 h
after LPS treatment (Fig. 5 f). However, F4/801 cells
were detected in naive mice (Fig. 5 e) as well as at earlier
time points after LPS injection in the CCR42/2 mice (data
not shown). These results may imply a defect in the ability
of CCR42/2 mice to retain a particular macrophage popu-
lation expressing F4/80, in the peritoneum, which in turn
may confer LPS resistance in CCR42/2 mice.
The F4/80 antigen is an unusual seven-transmembrane
receptor in that its extracellular domain is composed of
EGF domain repeats. Its ligand(s) and precise function re-
main unknown (32), but while it is well established that ac-
tivated macrophages express F4/80, a population of CD51
peritoneal B cells has also recently been shown to express
this marker (33). Interestingly, we also noted a decrease in
the number of lymphocytes in the peritoneal lavage 24 h
after high dose LPS treatment in CCR42/2 mice (results
not shown). However, the identity of the affected lympho-
cyte population and its contribution, if any, to the mecha-
nism of LPS resistance in CCR42/2 mice awaits further in-
vestigation.
Resistance to LPS-induced lethality has now been dem-
onstrated in several gene-deleted mice, including macro-
phage migration inhibition factor (MIF [34]), intercellular
adhesion molecule 1 (ICAM-1 [35]), and TNF-RI (36),
although CCR4-deficient mice are unique in that they can
be resistant in both the high and low dose models of LPS-
induced endotoxic shock. A great deal is known about the
proinflammatory cytokine production after LPS treatment,
yet relatively little about the signal transduction pathway by
which LPS induces host cell activation. In the currently ac-
cepted model, LPS monomers are catalytically transferred
by a lipid exchange molecule, LBP (37), to CD14 (38).
The LPS transmembrane coreceptor, Toll-like receptor 4
(Tlr4), interacts with the LPS–CD14 complex and initiates
LPS signaling (39). The mechanism by which CCR4-defi-
cient mice are resistant to LPS is unclear, but may be due
to a difference in downstream signaling events. The use of
gene microarrays may help to elucidate the differences be-
tween the CCR41/1 and CCR42/2 mice in this respect.
In conclusion, we have shown that 24 h after high dose
LPS treatment there is a significant reduction in the num-
bers of macrophages found in the peritoneum of CCR42/2
mice. At the same time, we noted a decrease in macro-
phage-associated serum cytokines TNF-a, IL-1b, and MIP-
1a. In addition, peritoneal lavage cells had decreased levels
of mRNA for the chemokines MDC and MIP-2, which
are thought to be produced mainly by activated macro-
phages. Taken together, these results are consistent with ei-
ther a defect in macrophage function or the absence of a
specific population, which is supported by the disappear-
ance of the F4/801 population at 24 h after LPS treatment.
Identification of the precise mechanisms of LPS-induced
cell stimulation is important for our understanding of bac-
terial pathogenesis and for the development of strategies to
protect against gram-negative bacterial infection. Targeted
deletion of the CCR4 gene has revealed an unexpected
role for this receptor in LPS-induced endotoxic shock.
Thus, although there is only limited relevance of the en-
dotoxic shock models used here in mice, to the condition
of septic shock in humans, it remains to be seen whether
neutralization of CCR4 either by antibodies or chemokine
receptor antagonists will have any therapeutic effect in
vivo. Further studies with this animal model should also
help elucidate the role of CCR4 in immunity, inflamma-
tion, and other biological functions.
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